Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 319,800 shares, an increase of 1,284.4% from the March 15th total of 23,100 shares. Approximately 26.2% of the shares of the stock are short sold. Based on an average trading volume of 386,500 shares, the days-to-cover ratio is presently 0.8 days.

Virpax Pharmaceuticals Stock Down 16.7 %

Shares of NASDAQ VRPX traded down $0.04 during midday trading on Monday, reaching $0.20. The company’s stock had a trading volume of 11,274 shares, compared to its average volume of 200,536. Virpax Pharmaceuticals has a one year low of $0.13 and a one year high of $101.00. The company has a 50 day moving average price of $3.99 and a 200 day moving average price of $9.18.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC purchased a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals at the end of the most recent quarter. Institutional investors own 32.23% of the company’s stock.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.